Cargando…

Efficacy and safety of targeted therapy for metastatic HER2-positive breast cancer in the first-line treatment: a Bayesian network meta-analysis

PURPOSE: Numerous HER2-targeted therapy clinical trials have demonstrated efficacy and safety in the first-line treatment of metastatic breast cancer (MBC). However, the direct or indirect comparison of these drugs is unclear. This network meta-analysis can solve this issue to some extent. MATERIALS...

Descripción completa

Detalles Bibliográficos
Autores principales:	Feng, Fubin, Zhang, Tingting, Yin, Fang, Liu, Cun, Zhuang, Jing, Qi, Lingyu, Wang, Xue, Li, Jia, Wang, Lu, Tian, Jinhui, Sun, Changgang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6362967/ https://www.ncbi.nlm.nih.gov/pubmed/30774382 http://dx.doi.org/10.2147/OTT.S187739

Ejemplares similares

Development of a risk scoring system for evaluating the prognosis of patients with Her2-positive breast cancer
por: Gao, Chundi, et al.
Publicado: (2020)

Effect of first-line endocrine therapy in patients with hormone-sensitive advanced breast cancer: a network meta-analysis
por: Zhang, Tingting, et al.
Publicado: (2018)

Comparative efficacy of different targeted therapies plus fulvestrant for advanced breast cancer following progression on prior endocrine therapy: a network meta-analysis
por: Zhang, Tingting, et al.
Publicado: (2018)

Comparative effectiveness of different chemotherapy regimens of advanced-stage Hodgkin lymphoma in adults: a network meta-analysis
por: Zhang, Tingting, et al.
Publicado: (2018)

Survival-Associated Metabolic Genes and Risk Scoring System in HER2-Positive Breast Cancer
por: Gao, Chundi, et al.
Publicado: (2022)

Efficacy and Safety of Anti-HER2 Targeted Therapy for Metastatic HR-Positive and HER2-Positive Breast Cancer: A Bayesian Network Meta-Analysis
por: Wu, Xian-Meng, et al.
Publicado: (2023)

First-line treatment of patients with HER2-positive metastatic gastric and gastroesophageal junction cancer
por: Esen, Selin Aktürk, et al.
Publicado: (2022)

Cryptotanshinone Is a Intervention for ER-Positive Breast Cancer: An Integrated Approach to the Study of Natural Product Intervention Mechanisms
por: Li, Huayao, et al.
Publicado: (2021)

Identification of lncRNAs associated with lung squamous cell carcinoma prognosis in the competitive endogenous RNA network
por: Qi, Lingyu, et al.
Publicado: (2019)

Efficacy and safety of de-escalation bone- modifying agents for cancer patients with bone metastases: a systematic review and meta-analysis
por: Liu, Cun, et al.
Publicado: (2018)

Trastuzumab combined with doublet or single-agent chemotherapy as first-line therapy for HER2-positive metastatic breast cancer
por: Yu, Y. F., et al.
Publicado: (2017)

Integrated analysis of co‐expression and ceRNA network identifies five lncRNAs as prognostic markers for breast cancer
por: Yao, Yan, et al.
Publicado: (2019)

Comparing efficacy and safety of first-line treatment of metastatic renal cell carcinoma: A Bayesian network meta-regression analysis
por: Qin, Suyang, et al.
Publicado: (2023)

Prognostic Value of Plasma HER2 Gene Copy Number in HER2-Positive Metastatic Breast Cancer Treated with First-Line Trastuzumab
por: Ran, Ran, et al.
Publicado: (2020)

Lapatinib plus Letrozole as First-Line Therapy for HER-2(+) Hormone Receptor–Positive Metastatic Breast Cancer
por: Schwartzberg, Lee S., et al.
Publicado: (2010)

First line chemotherapy plus trastuzumab in metastatic breast cancer HER2 positive - Observational institutional study
por: Aitelhaj, Meryem, et al.
Publicado: (2016)

HER2-positive metastatic cervical cancer responsive to first and second-line treatment: A case report
por: Fortman, Dylan, et al.
Publicado: (2019)

Economic Evaluation of First-Line Pertuzumab Therapy in Patients with HER2-Positive Metastatic Breast Cancer in Japan
por: Moriwaki, Kensuke, et al.
Publicado: (2021)

Target Analysis and Mechanism of Podophyllotoxin in the Treatment of Triple-Negative Breast Cancer
por: Zhang, Wenfeng, et al.
Publicado: (2020)

Gene signatures of 6-methyladenine regulators in women with lung adenocarcinoma and development of a risk scoring system: a retrospective study using the cancer genome atlas database
por: Gao, Chundi, et al.
Publicado: (2021)

Identifying the Effect of Ursolic Acid Against Triple-Negative Breast Cancer: Coupling Network Pharmacology With Experiments Verification
por: Zhang, Yubao, et al.
Publicado: (2021)

Construction and Analysis of Competing Endogenous RNA Networks for Breast Cancer Based on TCGA Dataset
por: Wang, Xue, et al.
Publicado: (2020)

Clinicopathological characteristics and prognostic value of the cancer stem cell marker ALDH1 in ovarian cancer: a meta-analysis
por: Zhao, Wenge, et al.
Publicado: (2018)

Chemotherapy Options beyond the First Line in HER-Negative Metastatic Breast Cancer
por: Lorusso, Vito, et al.
Publicado: (2020)

Efficacy and clinical outcome of chemotherapy and endocrine therapy as first-line treatment in patients with hormone receptor-positive HER2-negative metastatic breast cancer
por: Yuan, Yang, et al.
Publicado: (2023)

Preferences for the sequencing of first-line systemic treatments in metastatic hormone receptor-positive, HER2-negative breast cancer
por: Al Mahmasani, Layal, et al.
Publicado: (2023)

Trastuzumab Plus Endocrine Therapy or Chemotherapy as First-line Treatment for Patients with Hormone Receptor–Positive and HER2-Positive Metastatic Breast Cancer (SYSUCC-002)
por: Hua, Xin, et al.
Publicado: (2022)

Cost-effectiveness of trastuzumab biosimilar combination therapy and drug wastage as first-line treatment for HER2-positive metastatic breast cancer
por: Leung, John Hang, et al.
Publicado: (2022)

SNP mutation‐related genes in breast cancer for monitoring and prognosis of patients: A study based on the TCGA database
por: Gao, Chundi, et al.
Publicado: (2019)

7-lncRNA Assessment Model for Monitoring and Prognosis of Breast Cancer Patients: Based on Cox Regression and Co-expression Analysis
por: Li, Huayao, et al.
Publicado: (2019)

Tumor Mutation Burden and Immune Invasion Characteristics in Triple Negative Breast Cancer: Genome High-Throughput Data Analysis
por: Gao, Chundi, et al.
Publicado: (2021)

First-line chemotherapy regimens for locally advanced and metastatic pancreatic adenocarcinoma: a Bayesian analysis
por: Zhang, Shuisheng, et al.
Publicado: (2018)

First-line therapy in HER2 positive metastatic breast cancer: is the mosaic fully completed or are we missing additional pieces?
por: Fabi, Alessandra, et al.
Publicado: (2016)

Capecitabine Plus Aromatase Inhibitor as First Line Therapy for Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer
por: Alvarado-Miranda, Alberto, et al.
Publicado: (2023)

Trastuzumab, leuprorelin, letrozole, and palbociclib as first-line therapy in HER2-positive and hormone receptor-positive metastatic breast cancer: A case report
por: Sun, Maoben, et al.
Publicado: (2023)

Identifying the Antiproliferative Effect of Astragalus Polysaccharides on Breast Cancer: Coupling Network Pharmacology With Targetable Screening From the Cancer Genome Atlas
por: Liu, Cun, et al.
Publicado: (2019)

First-line treatment of unresectable or metastatic HER2 positive esophagogastric adenocarcinoma: liquid biomarker analysis of the phase 2 INTEGA trial
por: Paschold, Lisa, et al.
Publicado: (2023)

Safety and efficacy of vinorelbine in combination with pertuzumab and trastuzumab for first-line treatment of patients with HER2-positive locally advanced or metastatic breast cancer: VELVET Cohort 1 final results
por: Perez, Edith A., et al.
Publicado: (2016)

Chemotherapy or endocrine therapy, first-line treatment for patients with hormone receptor-positive HER2-negative metastatic breast cancer in China: a real-world study
por: Yuan, Yang, et al.
Publicado: (2021)

Vinorelbine plus trastuzumab combination as first-line therapy for HER 2-positive metastatic breast cancer patients: an international phase II trial
por: Chan, A, et al.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_3luue0rf8in3cb21nlqvfc1mc1